首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   4231450篇
  免费   339926篇
  国内免费   15124篇
耳鼻咽喉   59100篇
儿科学   132361篇
妇产科学   113557篇
基础医学   646346篇
口腔科学   119583篇
临床医学   383444篇
内科学   763908篇
皮肤病学   106571篇
神经病学   355211篇
特种医学   166737篇
外国民族医学   694篇
外科学   646274篇
综合类   124138篇
现状与发展   24篇
一般理论   2591篇
预防医学   348735篇
眼科学   98241篇
药学   298987篇
  24篇
中国医学   11663篇
肿瘤学   208311篇
  2021年   55593篇
  2019年   58478篇
  2018年   73092篇
  2017年   55616篇
  2016年   61455篇
  2015年   74931篇
  2014年   109260篇
  2013年   174649篇
  2012年   113666篇
  2011年   117163篇
  2010年   122520篇
  2009年   125350篇
  2008年   104535篇
  2007年   111461篇
  2006年   120139篇
  2005年   115401篇
  2004年   116840篇
  2003年   107273篇
  2002年   97326篇
  2001年   148504篇
  2000年   142877篇
  1999年   133720篇
  1998年   69353篇
  1997年   66095篇
  1996年   64035篇
  1995年   59343篇
  1994年   53639篇
  1993年   49966篇
  1992年   97932篇
  1991年   94197篇
  1990年   90512篇
  1989年   89002篇
  1988年   82931篇
  1987年   81113篇
  1986年   77727篇
  1985年   75712篇
  1984年   64526篇
  1983年   57588篇
  1982年   47247篇
  1981年   44041篇
  1980年   41599篇
  1979年   57183篇
  1978年   46881篇
  1977年   41725篇
  1976年   38295篇
  1975年   38983篇
  1974年   43127篇
  1973年   41767篇
  1972年   39711篇
  1971年   36720篇
排序方式: 共有10000条查询结果,搜索用时 187 毫秒
941.

Background

Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.

Patients and Methods

We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.

Results

Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.

Conclusions

FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients.  相似文献   
942.
Maternal and Child Health Journal - Background Prenatal substance use screening is recommended. The 4 P’s Plus screener includes questions on perceived problematic substance use in parents...  相似文献   
943.
944.
945.
ObjectiveClinical specialty societies recommend long-acting reversible contraceptives (LARCs) as first-line contraception for adolescent women. We evaluated whether a combined educational and process improvement intervention enhanced LARC placement in primary care within an integrated health care system.MethodsThe intervention included journal clubs, live continuing education, point-of-care guidelines, and new patient materials. We conducted a retrospective cohort study across 3 time periods: baseline (January 2013?September 2015), early implementation (October 2015–March 2016), and full implementation (April 2016–June 2017). The primary outcome was the proportion of LARCs placed by primary care clinicians among women aged 13 to 18 years compared with gynecology clinicians.ResultsKaiser Foundation Health Plan of Colorado cared for approximately 20,000 women aged 13 to 18 years in each calendar quarter between 2013 and 2017. Overall, LARC placement increased from 7.0 per 1000 members per quarter at baseline to 13.0 per 1000 during the full intervention. Primary care clinicians placed 6.2% of all LARCs in 2013, increasing to 32.1% by 2017 (P < .001), including 45.5% of contraceptive implants. Clinicians who attended educational sessions were more likely to adopt LARCs than those who did not (17.9% vs 6.4% respectively, P = .009). Neither overall LARC placement rates (relative risk, 1.9; 95% confidence interval, 0.7?5.6) nor contraceptive implant rates (relative risk, 3.0; 95% confidence interval, 0.9?9.8) increased significantly in clinicians who attended educational activities.ConclusionsThis multimodal intervention was associated with increased LARC placement for adolescent women in primary care. The combination of education and process improvement is a promising strategy to promote clinician behavior change.  相似文献   
946.
947.
948.
949.
李焱  翟凤霞 《陕西中医》2020,(5):660-662
妊娠期间,咳嗽不已,称"妊娠咳嗽",亦称"子嗽",孕妇咳嗽日久未见好转,咳嗽胸痛甚则咳而呕吐,或咳嗽剧烈或久咳不愈,可损伤胎气,导致堕胎、小产。笔者运用六经辨证治疗外感型中表寒里热证子嗽,认为此类患者病在太阳阳明,属于寒热错杂之表寒里热,采用《伤寒论》中方证麻杏甘石汤合止嗽散,使热从外泄,宣发卫气,散寒不助热、解表不伤正,故辨证论治取得了显著的疗效。同时子嗽治疗还需注意健脾固肾安胎,应将顾护胎元贯穿治疗妊娠咳嗽的始终。  相似文献   
950.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号